{"id":25076,"date":"2024-08-30T16:09:07","date_gmt":"2024-08-30T14:09:07","guid":{"rendered":"https:\/\/mabdesign.fr\/multiple-sclerosis\/"},"modified":"2025-03-27T10:55:00","modified_gmt":"2025-03-27T09:55:00","slug":"multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/multiple-sclerosis\/","title":{"rendered":"Multiple Sclerosis"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MabDesign’s market analyses give you a monthly overview of market dynamics and projects<\/span> in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the market and projects currently under development for the treatment of multiple sclerosis. <\/span><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system, causing progressive deterioration of motor and cognitive functions. It affects women two to three times more often<\/strong> than men, and the average age at diagnosis is young, between 20 and 40 years old. Its annual incidence is estimated at 2.5 to 5 cases per 100,000<\/strong> population, and its prevalence at 35.9 per 100,000. <\/p>\n

\n
\n
\n
\n

This prevalence has been rising steadily<\/strong> since the second half of the 20th century, and treating MS represents a major challenge for the pharmaceutical industry, particularly in the field of biomedicines, where new therapeutic approaches offer promising prospects for slowing the progression of the disease.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Epidemiological data<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

2,5-5<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

incidence per 100,000 inhabitants<\/strong><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

35,9<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

prevalence per 100,000 inhabitants<\/strong><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"femme\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

2x to 3x<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

more women than men affected<\/strong><\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Multiple sclerosis market and pipeline<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

As in the global drug market, the multiple sclerosis treatment market is dominated by small molecules, with only 5.9% of<\/strong> available products being biologics<\/strong>.
\nBy contrast, the boom in biopharmaceuticals and the hope they hold for the treatment of MS is illustrated by the pipeline, which contains 49.8% biopharmaceuticals.<\/strong> <\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Products on the market<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t
<\/h5><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Pipeline<\/h5>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t<\/canvas>\n\t\t<\/div>\n\n\t\t
<\/h5><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The pipeline is rich, with 506 products currently in development <\/strong>targeting the treatment of different types of multiple sclerosis.
\nMany different therapeutic strategies are explored in the products under development: vaccines, monoclonal antibodies, gene and cell therapies, etc. <\/p>\n

53 products are already in the clinical phase<\/strong>, monoclonal antibodies being the most advanced type of product: 9 mAbs are in phase III and one is currently in pre-registration.<\/strong> The product in pre-registration is ocrelizumab, a new formulation of an anti-CD20 antibody, which enables the product to be administered with two annual 10-minute subcutaneous injections, instead of intravenous infusions, which are more restrictive for patients.<\/p>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t
\n\t\t\n\t\t\t\t\t

\n\t\t\t\tPipeline par type de biom\u00e9dicaments et phase de d\u00e9veloppement\t\t\t<\/p>\n\t\t\t<\/div>\n\t\n

\n
\n <\/div>\n<\/div>\n